These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9427050)

  • 1. The effects of pretransplant conditioning, graft-versus-host disease and sepsis on the CRP levels in bone marrow transplantation.
    Rintala E; Remes K; Salmi TT; Koskinen P; Nikoskelainen J
    Infection; 1997; 25(6):335-8. PubMed ID: 9427050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of presumed sepsis from acute graft-versus-host disease by C-reactive protein and serum total IgE in bone marrow transplant recipients.
    Saarinen UM; Strandjord SE; Warkentin PI; Cheung NK; Lazarus HM; Coccia PF
    Transplantation; 1987 Oct; 44(4):540-6. PubMed ID: 3313843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein in the management of children with fever after allogeneic bone marrow transplantation.
    de Bel C; Gerritsen E; de Maaker G; Moolenaar A; Vossen J
    Infection; 1991; 19(2):92-6. PubMed ID: 2050427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation.
    Tvedt TH; Lie SA; Reikvam H; Rye KP; Lindås R; Gedde-Dahl T; Ahmed AB; Bruserud Ø
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27809289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality.
    Schots R; Kaufman L; Van Riet I; Lacor P; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 1998 Jul; 22(1):79-85. PubMed ID: 9678800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of interleukin 6, interleukin 8, and C-reactive protein after human allogeneic bone marrow transplantation.
    Schwaighofer H; Herold M; Schwarz T; Nordberg J; Ceska M; Prior C; Nachbaur D; Weyrer W; Brankova J; Eibl B
    Transplantation; 1994 Aug; 58(4):430-6. PubMed ID: 8073511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretransplant C-reactive protein as A prognostic marker in allogeneic stem cell transplantation.
    Jordan KK; Christensen IJ; Heilmann C; Sengeløv H; Müller KG
    Scand J Immunol; 2014 Mar; 79(3):206-13. PubMed ID: 24313319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT.
    Sato M; Nakasone H; Oshima K; Ishihara Y; Wada H; Sakamoto K; Kawamura K; Ashizawa M; Machishima T; Terasako K; Kimura S; Kikuchi M; Okuda S; Tanihara A; Yamazaki R; Tanaka Y; Kanda J; Kako S; Nishida J; Kanda Y
    Bone Marrow Transplant; 2013 May; 48(5):698-702. PubMed ID: 23042494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
    Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
    Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
    Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
    Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum IgE levels after bone marrow transplantation.
    Abedi MR; Bäckman L; Persson U; Ringdén O
    Bone Marrow Transplant; 1989 May; 4(3):255-60. PubMed ID: 2659111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Procalcitonin in comparison to C-reactive protein as markers of the course of sepsis in severely immunocompromised children after bone marrow transplantation].
    Sauer M; Tiede K; Volland R; Fuchs D; Zintl F
    Klin Padiatr; 2000; 212(1):10-5. PubMed ID: 10719677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in plasma fibronectin during allogeneic bone marrow transplantation.
    Norfolk DR; Bowen M
    J Clin Pathol; 1985 Oct; 38(10):1185-8. PubMed ID: 3902903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous interleukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy.
    Schwaighofer H; Oberhuber G; Hebart H; Einsele H; Herold M; Nachbaur D; Eibl B; Tilg H; Kropshofer G; Ferrara JL; Niederwieser D
    Transplantation; 1997 Jan; 63(1):52-6. PubMed ID: 9000660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cataract-free interval and severity of cataract after total body irradiation and bone marrow transplantation: influence of treatment parameters.
    van Kempen-Harteveld ML; Struikmans H; Kal HB; van der Tweel I; Mourits MP; Verdonck LF; Schipper J; Battermann JJ
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):807-15. PubMed ID: 11020578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease.
    Miralbell R; Bieri S; Mermillod B; Helg C; Sancho G; Pastoors B; Keller A; Kurtz JM; Chapuis B
    J Clin Oncol; 1996 Feb; 14(2):579-85. PubMed ID: 8636774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.